New drug HY6725 enters first human safety tests

NCT ID NCT07262281

Recruiting now Knowledge-focused Sponsor: Newsoara Biopharma Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing an experimental drug called HY6725 in 74 healthy adults to see if it is safe and how the body processes it. Participants receive either the drug or a placebo as a single injection or two injections one month apart. The study does not aim to treat any disease, but to gather essential safety and dosing information for future research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

HY6725 (an experimental biologic injection)

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Nucleus Network Pty Ltd.
RECRUITING

Melbourne, Australia

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••